Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (16613)	3/7/1998 7:46:00 AM
From: Henry Niman	Respond to of 32384

Here's what Dow Jones said: Dow Jones Newswires -- March 6, 1998 R.P. Scherer, Ligand Pharma To Develop Oral Capsules Dow Jones Newswires TROY, Mich. -- R.P. Scherer Corp. (SHR) is collaborating with its customer, Ligand Pharmaceuticals Inc. (LGND), on Ligand's Panretin and Targretin oral capsules. In a press release Friday, the companies said the products are softgel formulations within a new category of drug products called retinoids, which may be useful in the treatment of various cancers, dermatological diseases, and metabolic diseases. Drug company Ligand and R.P. Scherer, a maker of drug delivery systems, jointly developed the softgel formulations for the Ligand products in a project dating to January 1993, and the products are expected to be commercialized in 1999 and 2000. Panretin oral capsules are in single-agent Phase II trials and in a Phase I trial in combination with interferon for patients with AIDS-related Kaposi's sarcoma. Phase II trials are ongoing in breast, ovarian, and pediatric cancers, bronchial metaplasia and myelodysplastic syndrome, and a study in severe plaque psoriasis has been completed. Targretin oral capsules are in Phase II/III registration trials for cutaneous T-Cell lymphoma and in ongoing Phase II trials for type II diabetes, head and neck, lung, ovarian and prostate cancers, systemic Kaposi's sarcoma and Psoriasis.